Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,209 across all filing types
Latest filing 2021-02-28 Board/Management Inform…
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
Botanix Expands Management Team 3 pages 154.2KB
Board/Management Information Classification · 100% confidence The document is a press release dated 1 March 2021 announcing the expansion of the management team at Botanix Pharmaceuticals, including new hires and the resignation of an executive director. It focuses on personnel changes and company strategy related to clinical and commercial activities. There are no financial statements, regulatory filings, or detailed financial data presented. The content is clearly about changes in senior management and board membership. Therefore, the document fits the category of Board/Management Information (MANG). The document length (8079 characters) supports it being a full announcement rather than a brief note or a report publication announcement.
2021-02-28 English
Half Yearly Report and Accounts 21 pages 750.3KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4D Half-yearly report' and explicitly states it is a half-year report for the period ended 31 December 2020. It contains detailed financial statements such as consolidated statement of profit or loss, statement of financial position, cash flows, notes to financial statements, directors' report, and auditor's review report. The presence of comprehensive financial data and analysis for a half-year period confirms it is an Interim / Quarterly Report. The document is about 15,000 characters long, indicating it is the full report, not just an announcement or certification. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report).
2021-02-25 English
Presentation - Dermatology Drug Development Summit Europe 26 pages 4.2MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by Botanix Pharmaceuticals Limited about their clinical stage cannabinoid products, including clinical trial progress, scientific data, and near-term catalysts. It includes extensive information on their antimicrobial and dermatology drug development programs, clinical data, and scientific background. The document is dated 19 February 2021 and is structured as a presentation with slides and detailed content aimed at investors or industry experts. It is not a regulatory filing, audit report, earnings release, or announcement of voting results. It is not a brief factsheet or a short announcement but a comprehensive presentation of the company's strategy, pipeline, and clinical progress. Therefore, the document fits the definition of an Investor Presentation (IP). The document length is 15,000 characters, indicating it is a full presentation rather than a short announcement or report publication notice.
2021-02-18 English
Botanix receives A$6.87m R&D Tax Incentive Refund 2 pages 197.7KB
Capital/Financing Update Classification · 95% confidence The document is a press release dated 12 February 2021 announcing that Botanix Pharmaceuticals has received an R&D Tax Incentive Refund of A$6.87 million for the 2019/2020 financial year. It also mentions the company's cash position as of 31 December 2020 and recent positive clinical study data. The content focuses on a financial update related to funding and cash position, with no detailed financial statements or comprehensive financial performance data. The document is relatively short (about 5,078 characters) and reads as a corporate announcement rather than a full financial report. It does not contain quarterly or annual financial results, nor does it include detailed management discussion or audit information. Therefore, it fits best under Capital/Financing Update (CAP) as it provides an update on company funding and financial position related to the R&D tax refund and cash holdings, which impacts the company's capital and financing flexibility.
2021-02-11 English
Phase 2a Study Shows BTX 1801 Eradicates S. Aureus 4 pages 240.2KB
Regulatory Filings Classification · 95% confidence The document is a press release dated 3 February 2021 from Botanix Pharmaceuticals announcing top-line data from a Phase 2a clinical study of their BTX 1801 product. It details study design, endpoints, results, and future development plans. The content focuses on clinical trial results and company updates rather than financial data or regulatory filings. There is no indication that this is a full financial report, audit report, or regulatory filing. It is not a transcript, capital update, or governance document. The document is a corporate announcement of clinical trial results and company progress, which fits best under the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2021-02-02 English
Trading Halt 2 pages 571.0KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Botanix Pharmaceuticals Limited regarding a trading halt requested under ASX Listing Rule 17.1. The purpose of the trading halt is to allow the company to release an announcement about the results of a Phase 2a antimicrobial study. The document is short (2188 characters) and does not contain any financial data, report content, or detailed analysis. It is an announcement about a trading halt, not a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-01-31 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.